Results for 3 of these 36 comparisons (one permuted dose group compared against placebo for 3 of the 9 endpoints), and the number of endpoint comparisons out of 9 with a positive trend for that dose group, are shown for the 10 illustrative permutation samples in Table 3 .
← all excerpts
Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF.
1
—
—